10-Q: Ecomax Inc. Reports Q3 Results: Revenue Increases but Losses Persist Amid Going Concern Uncertainty

Ecomax Inc.'s Q3 2024 report shows increased revenue but ongoing net losses and negative working capital, raising concerns about its ability to continue as a going concern.

Summary

• Ecomax, Inc. reported its financial results for the quarter ended March 31, 2024.
• The company's revenue increased to $108,824 for the quarter, compared to $96,221 for the same period last year.
• However, the company continues to experience net losses, with a net loss of $18,529 for the quarter and $41,793 for the nine-month period.
• The company's financial statements have been prepared assuming it will continue as a going concern, but there is substantial doubt about its ability to do so.
• As of March 31, 2024, the company had no cash and negative working capital of $339,403.
• The company is dependent on funding from a significant shareholder to meet its operating expenses.
• The company's independent auditors have expressed uncertainty about its ability to continue as a going concern.
• The company is actively engaged in the distribution of personal healthcare products and nutrition supplements, specifically Rocitin NMN.
• The company relies on a distributor agreement with Rocitin Company Limited, sharing gross profits on a 50/50 basis.
• The company's common stock is subject to quotation on the OTC Pink Sheets under the symbol EMAX.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's ongoing net losses, negative working capital, dependence on related party funding, and uncertainty about its ability to continue as a going concern. While revenue has increased, the overall financial situation is precarious.

Positives

• Revenue increased for both the three and nine months ended March 31, 2024, compared to the same periods in 2023.
• The net loss decreased for both the three and nine months ended March 31, 2024, compared to the same periods in 2023.
• The company has a Loan Agreement with a significant shareholder, providing access to funding up to $800,000.
• The company has a distribution agreement in place to sell Rocitin NMN products.

Negatives

• The company continues to experience net losses.
• The company has no cash and negative working capital.
• The company is dependent on funding from a significant shareholder.
• The company's auditors have expressed uncertainty about its ability to continue as a going concern.
• The company's disclosure controls and procedures were deemed ineffective due to material weaknesses.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company is dependent on funding from a related party, which may not be sustainable.
• The company's common stock is subject to quotation on the OTC Pink Sheets, which may limit trading activity.
• The company's disclosure controls and procedures are ineffective, which could lead to inaccurate financial reporting.
• The company has limited capital and may need additional financing.

Future Outlook

The company's future is dependent on management's success in its efforts and limited resources to conduct current business. The company is evaluating strategic alternatives but cannot assure that any actions will raise sufficient capital.

Industry Context

The company operates in the personal healthcare products and nutrition supplements industry, which is competitive and subject to changing consumer preferences and regulations. The company's reliance on a single product (Rocitin NMN) and a single distributor (Rocitin Company Limited) makes it vulnerable to market shifts and supply chain disruptions.

Comparison to Industry Standards

• It is difficult to compare Ecomax's results to industry standards due to its small size, limited operating history, and OTC Pink Sheets listing.
• Companies in the nutrition supplement industry often have higher gross margins and more diversified product lines.
• Many comparable companies have stronger balance sheets and access to capital markets.
• Ecomax's reliance on related party funding is not typical of established companies in the industry.

Related Party Transactions

• The company has a Loan Agreement with New York Listing Management Inc., a significant shareholder, under which it receives funding for general operating expenses.
• Purchases of inventory for sale are financed by the Loan Agreement with its significant shareholder, NYLM.
• The Loan Agreement also gives the right to NYLM to collect cash receipts from sales of the inventory on the Companys behalf based on a profit-sharing arrangement the Company has with the Distributor.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and uncertainty about its ability to continue as a going concern.
• Employees' jobs are at risk if the company is unable to secure funding and sustain operations.
• Customers may be affected if the company is unable to fulfill orders or provide ongoing support.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company plans to satisfy its cash requirements for the next 12 months through borrowings from New York Listing Management, Inc, as well as from the revenue generated from operations.
• The company intends to repay the loan from NYLM at a time when it has the cash resources to do so.
• The company intends to take corrective actions to address the ineffective disclosure controls and procedures in the future when it generates sufficient profits to do so.

Key Dates

Keywords

Ecomax, Financial Results, Going Concern, Rocitin NMN, Net Loss, Revenue, OTC Pink Sheets, Loan Agreement, Related Party Transactions, Healthcare Products, Nutrition Supplements